Your session is about to expire
← Back to Search
Ruxolitinib + Thalidomide for Myelofibrosis
Study Summary
This trial is testing the effects of two drugs, ruxolitinib and thalidomide, on cancer. The drugs may help to shrink the cancer, but they may also cause side effects.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 149 Patients • NCT02038036Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had a blood clot in my veins or lungs in the last 6 months.I am 18 years or older.I have been treated with Thalidomide and Ruxolitinib together.I haven't taken cancer drugs other than hydroxyurea or Ruxolitinib recently.You have had a serious allergic reaction to Thalidomide in the past, which caused a rash that peeled off the skin.I only have the cancer this study is targeting, or a non-aggressive cancer that's been treated.I can care for myself and am up and about more than 50% of my waking hours.My organs are functioning well.I am committed to following strict birth control measures and pregnancy testing if I can have children.I am on Ruxolitinib but it's not working well enough for my condition.My total bilirubin level is 2.0 mg/dL or lower, unless I have Gilbert's disease.My liver enzymes are within the allowed range for the trial.I have myelofibrosis needing treatment, regardless of previous treatments or being newly diagnosed with a certain risk level.I have been on a stable dose of Ruxolitinib for at least 4 weeks.I can swallow pills.I am not taking any strong drugs that affect liver enzyme CYP3A4.
- Group 1: Cohort B: Ruxolitinib and Thalidomide
- Group 2: Cohort A: Ruxolitinib and Thalidomide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper limit of participants in this medical study?
"This trial is no longer recruiting participants. It was initially advertised on February 27th 2017 and last updated Aug 23rd 2022. However, there are 109 studies in search of individuals with primary myelofibrosis and 124 Ruxolitinib trials that still need candidates."
How is Ruxolitinib typically deployed to manage health issues?
"Ruxolitinib is the go-to medication for multiple myeloma, yet it also has proven efficacy in treating disease, polycythemia vera and related conditions."
Is this experiment currently recruiting participants?
"This research venture is no longer actively enrolling patients. It was originally posted on February 27 2017 and was last edited on August 23 2022. If you are searching for alternative trials, there currently exist 109 clinical studies seeking participants with primary myelofibrosis as well as 124 Ruxolitinib based investigations that require volunteers."
Has the FDA sanctioned Ruxolitinib for medical use?
"Although Ruxolitinib has not been proven to be efficacious in clinical trials, there is some data indicating it can be safely administered. Our team at Power rated its safety a 2 on our scale of 1-3."
Have there been any prior experiments utilizing Ruxolitinib?
"Currently, 124 medical studies utilizing Ruxolitinib are underway with 22 being at the Phase 3 level. Of these trials, 4067 sites worldwide are actively recruiting patients and a notable concentration of them is located in Beijing."
How many North American institutions are conducting the research?
"This trial is currently open for enrolment at 7 distinct locations, which include Harrison, Houston and New york City. Furthermore, other cities provide access to this research opportunity as well; thus it's advisable to pursue the closest option in order to minimize travelling demands."
Share this study with friends
Copy Link
Messenger